LT2013109A - Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai - Google Patents

Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai

Info

Publication number
LT2013109A
LT2013109A LT2013109A LT2013109A LT2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A
Authority
LT
Lithuania
Prior art keywords
infections
atherosclerosis
cardivascular
prevention
antisense oligonucleotide
Prior art date
Application number
LT2013109A
Other languages
English (en)
Other versions
LT6214B (lt
Inventor
Ericson
Kačergius
Original Assignee
Uab "Bioseka"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab "Bioseka" filed Critical Uab "Bioseka"
Priority to LT2013109A priority Critical patent/LT6214B/lt
Priority to PCT/IB2014/065084 priority patent/WO2015052630A1/en
Publication of LT2013109A publication Critical patent/LT2013109A/lt
Publication of LT6214B publication Critical patent/LT6214B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Šis išradimas yra iš mikrobiologijos srities. Išradimas siūlo priešprasminius oligonukleotidus (PO), farmacines kompozicijas, apimančias PO, būdą slopinti bakterinių bioplėvelių atsiradimą ir augimą žmogaus kardiovaskuliniuose audiniuose ir žmogaus kraujo terpėje, siekiant aterosklerozės ir kardiovaskulinių infekcijų prevencijos ir gydymo.
LT2013109A 2013-10-07 2013-10-07 Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai LT6214B (lt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LT2013109A LT6214B (lt) 2013-10-07 2013-10-07 Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai
PCT/IB2014/065084 WO2015052630A1 (en) 2013-10-07 2014-10-06 Antisense oligonucleotides for prevention of atherosclerosis and cardiovascular infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2013109A LT6214B (lt) 2013-10-07 2013-10-07 Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai

Publications (2)

Publication Number Publication Date
LT2013109A true LT2013109A (lt) 2015-04-27
LT6214B LT6214B (lt) 2015-08-25

Family

ID=51871111

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2013109A LT6214B (lt) 2013-10-07 2013-10-07 Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai

Country Status (2)

Country Link
LT (1) LT6214B (lt)
WO (1) WO2015052630A1 (lt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US6228982B1 (en) 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
GB9211979D0 (en) 1992-06-05 1992-07-15 Buchard Ole Uses of nucleic acid analogues
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
GB2284209A (en) 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
US5705333A (en) 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
CA2258011A1 (en) * 1996-06-21 1997-12-24 Virginia Commonwealth University Vaccine to prevent streptococcal endocarditis
US6107470A (en) 1997-05-29 2000-08-22 Nielsen; Peter E. Histidine-containing peptide nucleic acids
NZ556114A (en) * 2004-12-06 2010-02-26 Kane Biotech Inc Peptides capable of inhibiting Streptococcus mutans genetic competence and biofilm formation
WO2014033314A1 (en) * 2012-09-03 2014-03-06 Uab Bioseka Antisense oligonucleotide targeting bacterial glucosyltransferases

Also Published As

Publication number Publication date
LT6214B (lt) 2015-08-25
WO2015052630A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
WO2014062720A3 (en) Methods of treating cancer
HK1213889A1 (zh) 殼氨醯胺酶抑制劑及使用方法
NZ700759A (en) Combination therapy for treating cancer
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2013120022A3 (en) Treatment of hypoglycemia
MX372858B (es) Sistemas y métodos de tratamiento de agua.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2014013752A (es) Inhibidores de nampt.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12014502513A1 (en) Nampt inhibitors
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
GB2496342B (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX344590B (es) Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos.
MX348397B (es) Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico.
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors

Legal Events

Date Code Title Description
BB1A Patent application published

Effective date: 20150427

FG9A Patent granted

Effective date: 20150825

MM9A Lapsed patents

Effective date: 20161007